Choose your language
en nl

Nanobiotix

Nanobiotix is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer

  • Nanobiotix completed a sub-10% private placement by issuing new shares  to US and EU institutional investors
  • Proceeds will be used for the development of lead product NBTXR3 and preparation of its market access and launch
  • Order book was of mainly long-only demand was covered by  a majority of new institutional investors and institutional investors from the US
Van Lanschot